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Results of treatment with anticancer agents have steadily
improved over the years following the introduction of more
effective drugs and the establishment of better designed
chemotherapy strategies. Still, chemotherapy failure due to
cellular drug resistance remains a major problem in most
cancer patients. Using cell lines made resistant to anticancer
agents, several types of drug resistance have been character-
ised, among which are alterations in target proteins (Cabral
et al., 1980; Flintoff & Essani, 1980), carrier mediated drug
uptake (Redwood & Colvin, 1980; Sirotnak et al., 1981),
cellular drug metabolism (Aronow et al., 1984) and cellular
repair mechanisms (Bedford & Fox, 1982). A very intriguing
development in drug resistance research is the discovery of
the phenomenon of multidrug resistance (MDR) (Bradley et
al., 1988; van der Bliek & Borst, 1989).
In MDR cells, selection for resistance to 'naturally
occurring' drugs, e.g. anthracyclines, vinca alkaloids, podo-
phyllotoxins, and colchicine, results in the development of
cross-resistance to other members of the MDR drug family
(Bech-Hansen et al., 1976; Dan0, 1972; Inaba & Johnson,
1977; Skovsgaard, 1978). The MDR related drugs are struc-
turally dissimilar and have different intracellular targets.
What these drugs have in common is that they are lipophilic
compounds derived from various natural products. In gen-
eral, MDR cells are not cross-resistant to alkylating agents
(e.g. chlorambucil and cyclophosphamide), antimetabolites
(e.g. cytarabine, methotrexate, and 5-fluorouracil), or cis-
platin.
A striking feature of the classical MDR phenotype is its
reduced ability to accumulate drugs, as compared to the
parent cell lines. This reduced drug accumulation is most
likely the main cause of multidrug resistance (Dan0, 1973;
Kessel & Bosmann, 1970; Riehm & Biedler, 1972; Sirotnak et
al., 1986, among other references). It is assumed that the
reduced drug accumulation is due to activity of an energy
dependent unidirectional drug efflux pump with broad sub-
strate specificity. This drug pump is composed of a trans-
membrane glycoprotein (P-glycoprotein) with a molecular
weight of 170 kD (Chen et al., 1986; Gerlach et al., 1986;
Gros et al., 1986). It uses energy in the form of ATP to
transport drugs through a channel formed by the transmem-
brane segments (Hamada & Tsuruo, 1988; Horio et al.,
1988).
Different P-glycoprotein isoforms have been identified, and
these are encoded by a family of closely related genes. They
are referred to as pgp genes in hamsters and mdr genes in
humans and mice (Ng et al., 1989). In humans, two P-glyco-
protein isoforms (mdrl and mdr3) with 80% amino acid
homology have been identified (Roninson et al., 1986; van
der Bliek et al., 1987). By cross-hybridisation of human
genomic DNA, Roninson and co-workers isolated two mdr
specific genomic clones designated as mdrl and mdr2 (Ronin-
son et al., 1986). Independently, Borst and co-workers iso-
lated mdr clones from cDNA libraries prepared from human
liver tissue and the human liver cell line HepG2 (van der
Bliek et al., 1987). Sequences for two mdr genes were iso-
lated. One corresponded to the previously reported human
mdrl sequence (Chen et al., 1986); the other appeared to be
the human homologue of the hamster pgp3 gene and was
therefore called mdr3 (van der Bliek et al., 1987; van der
Bliek et al., 1988a). It is now known that the mdr3 gene of
Borst et al. is identical in sequence to the mdr2 gene of
Roninson et al. (Chin et al., 1989). Both the human mdrl
and mdr3 genes were found to be localised on the long arm
ofchromosome 7 (Callen et al., 1987) and to be linked within
330 kilobases (Chin et al., 1987). Direct proof for the role of
mdrl in MDR was obtained by transfection experiments.
Expression of a full length cDNA clone of the human mdrl
gene in a drug-sensitive cell conferred a complete MDR
phenotype (Ueda et al., 1987). However, the human mdr3
gene does not seem to be involved in drug resistance and no
function of the gene product has yet been identified (van der
Bliek et al., 1988a).
Expression of the mdrl gene in normal tissues
Using slot blot analysis Fojo et al. (1987b) reported substan-
tial expression of the human mdrl gene in normal adrenal,
kidney, jejunal, rectal, liver and lung tissues. Other organs
and tissues (skin, subcutaneous tissue, skeletal muscle, heart,
spleen, bone marrow, lymphocytes, oesophagus, stomach,
ovary, kidney cortex and spinal cord) had low or undetect-
able mdrl levels.
Expression was further studied at the cellular level by in
situ hybridisation and immunohistochemical techniques
(Cordon-Cardo et al., 1990; Thiebaut et al., 1987; van der
Valk et al., 1990). P-glycoprotein was mainly found in
specialised epithelial cells with secretory or excretory func-
tions. Thiebaut et al. (1987) used the monoclonal antibody
MRK16, which is directed against an external epitope of the
human P-glycoprotein (Hamada & Tsuruo, 1986). In the
liver, P-glycoprotein was found on the biliary surface of
hepatocytes and small biliary ductules, in the pancreas on the
luminal surface of the epithelial cells of small ductules and, in
the kidney, on the brush border of the proximal tubules. The
colon and jejunum both showed high levels of P-glycoprotein
on the luminal surfaces of the mucosa. Cordon-Cardo et al.
(1990) and van der Valk et al. (1990) reported P-glycoprotein
expression in other specialised epithelial cells such as the
sweat glands in the skin, cells lining the trachea and major
bronchi in the lung, glandular epithelial cells of the prostate,
breast endometrium and thyroid, acinar cells of the pancreas,
and trophoblasts in the placenta. P-glycoprotein expression
was also detected in capillary endothelial cells in the human
brain, suggesting a role of P-glycoprotein in the blood-brain
barrier (Cordon-Cardo et al., 1990). Although the natural
substrate for the mdrl gene encoded P-glycoprotein is not yet
known, these expression data suggest that the P-glycoprotein
drug efflux pump plays a role in the normal physiology of the
organism and in the process of detoxicification of xenobiotic
substances.
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Expression of the mdrl gene in tumours
It is an attractive hypothesis that the clinical observation of
resistance to multidrug based chemotherapy is due to
enhanced mdrl expression in the resistant tumour. Using
monoclonal antibodies or nucleic acid probes, many investi-
gators have screened tumour biopsies for mdrl expression.
Expression of mdrl has been detected in virtually all tumour
types, carcinomas, sarcomas, leukaemias, and lymphomas
(Tables I and II). Yet, the relevance of this phenomenon to
clinical drug-resistance is not understood. Here, we present
an overview of the literature on mdrl expression in human
tumour materials and discuss some aspects that in our
opinion are essential for a full appreciation of the role of mdr
in human cancer treatment.
Most of the studies on the expression of the mdrl gene in
human tumours have employed bulk techniques (Northern-,
Western- or dot blotting, and RNAase protection) for the
detection and quantification of P-glycoprotein or its mRNA.
The disadvantage of such techniques is that the frequently
observed contamination with nontumour cells in the biopsy
as well as the heterogeneity within the tumour cell population
with regard to the level of P-glycoprotein expression are
ignored (Epstein et al., 1989; Ma et al., 1987; Rothenberg et
al., 1989; Tsuruo et al., 1987; Weinstein et al., 1990). But
there are also studies that searched for expression of the gene
in individual cells, by using either immunohistochemistry
with specific antibodies or in situ hybridisation with specific
RNA probes. Although these in situ methods are more sub-
jective in interpretation than are bulk methods, they provide
specific information on, e.g. the percentage of mdr positive
cells, the expression levels in individual cells, the morphology
Table I Expression of mdrl in human solid tumours
Group I High mdrl expression levels at a highfrequency
Renal cell cancer Fojo et al., 1987a*
Kakehi et al., 1988
Goldstein et al., 1989
Kanamaru et al., 1989
Colon cancer Fojo et al., 1987b
Goldstein et al., 1989
Hepatocellular carcinoma Goldstein et al., 1989
Adrenocortical cancer Goldstein et al., 1989
Pheochromocytoma Goldstein et al., 1989
Pancreatic cancer Goldstein et al., 1989
Group II Intermediate mdrl expression levels at a lowerfrequency
Neuroblastoma
Soft tissue sarcomas
Breast cancer
Goldstein et al., 1989; 1990**
Bourhis et al., 1989a
Gerlach et al., 1987**
Chan et al., 1990**
Goldstein et al., 1989
Moscow et al., 1989*
Schneider et al., 1989**
Salmon et al., 1989
Keith et al., 1990
Group III Almost always undetectable or low mdrl expression levels
Ovarian cancer Gerlach et al., 1987*
Goldstein et al., 1989
Moscow et al., 1989*
Bourhis et al., 1989b**
Head and neck cancer Goldstein et al., 1989
Moscow et al., 1989
Wilms' tumour Goldstein et al., 1989
Oesophageal cancer Goldstein et al., 1989
Moscow et al., 1989
Bladder cancer Kakehi et al., 1988
Goldstein et al., 1989
Moscow et al., 1989
Lung cancer (small cell and Goldstein et al., 1989
non small cell) Moscow et al., 1989
Lai et al., 1989*
* Not indicated whether the patients had received prior chemo-
therapy. ** Studies that permit a comparison between untreated and
treated patients.
Table H Expression of mdrl in human haematological malignan-
cies
Tumour type Untreated* Treated* Reference(s)
AMLa 7/38 20/27 Ma et al., 1987
Goldstein et al., 1989
Holmes et al., 1989
Nooter et al., 1990a
Herweijer et al., 1990
ALLb 9/39 7/24 Fojo et al., 1987b
Goldstein et al., 1989
Rothenberg et al., 1989
Herweijer et al., 1990
CMLC chronic 0/3 10/10 Goldstein et al., 1989
Herweijer et al., 1990
blast 7/7 9/19 Tsuruo et al., 1987
Pirker et al., 1989
Herweijer et al., 1990
CLLd 11/14 23/36 Herweijer et al., 1990
Holmes et al., 1990
Multiple 5/10 15/21 Dalton et al., 1989a; 1989b
myeloma Epstein et al., 1989
Non-Hodgkin's 8/31 9/19 Goldstein et al., 1989
lymphoma Dalton et al., 1989b
Moscow et al., 1989
Salmon et al., 1989
* Number ofpatients with mdrl expression/total number ofpatients
investigated. aAcute myelocytic leukaemia. bAcute lymphocytic leu-
kaemia. cChronic myelocytic leukaemia, chronic phase or blast crisis.
dChronic lymphocytic leukaemia.
of the mdr expressing cells and the localisation of the mdr
expressing cells in tumours. A tumour with a low percentage
of cells expressing high levels of mdrl might give a low level
of expression on average. Yet, such a small clone of high
mdrl expressers may be sufficient to prevent effective chemo-
therapy in the patient.
The literature data on the detection of mdrl expression in
solid tumours are summarised in Table I. Bulk techniques
were used in all studies, except for those of Schneider et al.
(1989), Salmon et al. (1989) and Chan et al. (1990), in which
immunohistochemistry was used. In most studies, the tumour
samples were obtained from patients who had not received
prior chemotherapy. In some, treatment status was not indi-
cated (Fojo et al., 1987a; Gerlach et al., 1987; Lai et al.,
1989; Moscow et al., 1989) and only a few compared both
treated and untreated tumour samples (Bourhis et al., 1989a,
b; Chan et al., 1990; Gerlach et al., 1987; Goldstein et al.,
1989; Schneider et al., 1989). We have arbitrarily divided the
solid tumours into three expression groups. For tumours in
all three groups, controversial reports on mdrl expression
levels have been published, which to a great extent can be
attributed to methodological differences, among others, the
sensitivity of the applied assays. Therefore, we have placed
the tumours in a specific group based on a general judgement
and the selection of literature references in Tables I and II is
provided to support this classification.
Group I represents the tumours that developed from tis-
sues normally expressing intermediate to high mdrl levels,
e.g. colon, liver, kidney, adrenal and pancreas. Clinically,
these tumours are all intrinsically drug resistant, i.e. have a
very low response rate to chemotherapy. In these, high mdrl
expression levels are frequently found, although, even in this
group, incidental tumour biopsies with undetectable levels of
mdrl have been encountered.
Group II includes the tumours that occasionally have high,
yet mostly intermediate mdrl expression levels, but also quite
often lack expression. This group contains the neuroblastomas,
soft tissue sarcomas, breast carcinomas, and, in our opinion,
the haematological malignancies (which we have placed in a
separate table (Table II) and which will be discussed below).
In general, group II tumours respond better to chemotherapy
than those of group I and even complete responses can be
achieved. Unfortunately, a high percentage of patients re-
lapse and become resistant to chemotherapy.
In tumours belonging to the last group (III), mostly un-
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observed. Remarkable are the results obtained with ovarian
tumours, which were placed in this group. The first report on
P-glycoprotein expression in human tumour materials
involved ovarian cancer (Bell et al., 1985). Two of five drug
resistant ovarian tumours showed relatively high P-glyco-
protein levels as quantified by Western blotting using the
C219 monoclonal antibody directed against an internal epi-
tope of the P-glycoprotein (Kartner et al., 1985). However,
later studies showed only low expression in three of a total of
88 ovarian tumours (Bourhis et al., 1989b; Gerlach et al.,
1987; Goldstein et al., 1989; Moscow et al., 1989). Never-
theless, the observation of Bell et al. has encouraged large
scale screening for expression of the mdrl gene in human
cancers. For group III tumours, chemotherapy can be effect-
ive, but, again, acquired chemoresistance is the rule rather
than the exception.
MDR related cytotoxic drugs represent a substantial part
of the chemotherapeutic arsenal for the treatment of haema-
tological malignancies. Furthermore, in these cancers, initial
periods of effective cytoreduction are often followed by a
state of acquired drug resistance, making them particularly
interesting to study with regard to MDR. The great advan-
tage of studying leukaemias is the ease of obtaining tumour
samples both before and after treatment. Therefore, in con-
trast to the solid tumours, many data are available on mdrl
expression in recurrent, chemotherapy treated haematological
malignancies. Expression of mdrl in such treated and un-
treated malignancies is summarised in Table II.
In normal haematopoietic cells (total bone marrow, spleen,
purified peripheral blood lymphocytes), only low to very low
mdrl expression levels are found (Fojo et al., 1987b; Holmes
et al., 1990). However, in almost all types of leukaemias,
multiple myelomas and non-Hodgkin's lymphomas, either
untreated or treated, elevated mdrl levels are reported. The
mdrl expression levels can range from low to high and even
in untreated tumours relatively high levels are sometimes
observed (Goldstein et al., 1989; Herweijer et al., 1990;
Nooter et al., 1990a). We can only speculate on the cause of
the elevated expression sometimes observed in the untreated
tumours. It is possible that the tumours developed by out-
growth of rare mdrl expressing cells present in the originat-
ing tissues or that the elevated mdrl expression developed as
a consequence of the malignant transformation (i.e., genetic
instability) which took place in the tumour cells.
Expression of the mdr3 gene
Using Northern and dot blotting assays, expression of the
human mdr3 gene has been detected only in the liver (van der
Bliek et al., 1988b). However, Roninson et al. used a very
sensitive and specific assay for human mdrl and mdr3 expres-
sion based on enzymatic amplificaiton of mRNA sequences
by polymerase chain reaction (Chin et al., 1989). In human
MDR cell lines, increased expression of mdrl mRNA was
paralleled by a smaller increase in levels of mdr3 mRNA,
suggesting that mdrl and mdr3 gene expression in these cells
may be regulated by a common mechanism. Using the same
technique, mdrl and mdr3 expression was analysed in normal
human tissues. In the colon, lung, stomach, oesophagus,
breast, muscles, and bladder, only mdrl expression was
detected (Chin et al., 1989). In the liver, kidneys, adrenals
and spleen, both mdrl and mdr3 expression was observed.
This distribution suggests that mdrl and mdr3 gene products
may be involved in some of the same processes or that
coexpression of these mRNAs may reflect a common regula-
tory pathway. Due to the high degree of homology between
the mdrl and mdr3 gene products, it was initially speculated
that the mdr3 gene also encodes for an efflux pump with
broad specificity (van der Bliek et al., 1988a). However, there
is no experimental evidence that the human mdr3 gene and
the homologous mouse mdr2 gene are involved in MDR;
transfection and expression of full length cDNA copies of
these genes inserted into mammalian expression vectors have
so far failed to induce resistance to drugs (Gros et al., 1988;
van der Bliek et al., 1988a).
We have recently found that, besides the mdrl gene, also
the mdr3 gene is expressed at relatively high levels in certain
types of human leukaemias (acute and chronic lymphocytic
leukaemia) (Herweijer et al., 1990). The available data sug-
gest that the mdr3 gene is selectively expressed in malignant
cells of the B-cell lineage, specifically in B-cell acute and
chronic lymphocytic leukaemia, B-cell prolymphocytic leu-
kaemia (PLL) and hairy cell leukaemia. PLL cells from
untreated patients appeared to express the mdr3 gene without
detectable levels of mdrl (Nooter et al., 1990a). In vitro drug
uptake studies showed that daunorubicin accumulation in
PLL cells was increased by cyclosporin A (Herweijer et al.,
1990; Nooter et al., 1990a). Since cyclosporins are inhibitors
of the mdrl encoded P-glycoprotein drug pump, the sugges-
tion is that mdr3 also can encode for a drug efflux pump in
PLL cells. These data are in contradiction with the earlier
mentioned transfection experiments and we cannot exclude
the possibility that the presence of mdr3 mRNA and cyclo-
sporin sensitive drug accumulation in PLL cells is merely
coincidental. Further studies are needed to answer the ques-
tion of whether mdr3 contributes to the primary resistance of
(B-cell) leukaemias.
Intrinsic and acquired MDR phenotype
In tumours developed from tissues that normally have a
substantial mdrl expression such as those of colon and kid-
neys, the mdrl expression is an inherent characteristic of the
tumour cells. There are several observations that suggest that
the MDR phenotype also can be acquired by tumours as a
consequence of chemotherapy. For some tumour types, high
mdrl expression levels are more frequently observed in treat-
ed tumours than in untreated ones. This has been found for
acute myeloid leukaemias (Goldstein et al., 1989; Herweijer
et al., 1990; Holmes et al., 1989; Nooter et al., 1990b),
neuroblastomas (Bourhis et al., 1989a; Goldstein et al., 1990)
and breast cancer (Schneider et al., 1989). It is very likely
that the acquisition ofmdrl expression by the tumour occurs
in the patient by selection of pre-existing mdrl expressing
cells. However, there is increasing evidence that the mdrl
promoter can be activated by chemical stress-inducing agents
(Chin et al., 1990; Kohno et al., 1989). Recently, it was
found that exposure of a human renal adenocarcinoma cell
line to sodium arsenite or cadmium chloride led to a 7- and
8-fold increase in mdrl mRNA and P-glycoprotien levels.
This increase in P-glycoprotein correlated with a transient
increase in resistance to vinblastine (Chin et al., 1990). In
another study, using an in vitro transient expression assay, it
was found that the mdrl promoter could be activated directly
by the addition of anticancer agents, including vincristine,
daunorubicin and doxorubicin (Kohno et al., 1989). These
data suggest that chemotherapeutic agents might themselves
directly cause the activation of the mdrl gene at the tran-
scription level.
Can mdrl expression account for clinical drug resistace?
Does the presence of mdrl expressing tumour cells limit
successful chemotherapy? This ofcourse, is the ultimate ques-
tion. One of the strongest pieces of evidence that mdrl
expression in vivo can induce acquired drug resistance, is
provided by a transgenic mouse model (Galski et al., 1989).
Transgenic mice expressing the human mdrl gene in the
haematopoietic tissues, appeared to be resistant to leuko-
penia induced by the anticancer agent daunomycin.
Expression levels of mdrl in human tumours can be as
high as those of in vitro generated MDR cell lines (Dalton et
al., 1989b; Fojo et al., 1987a; Goldstein et al., 1990; Herwei-
jer et al., 1990; Kanamaru et al., 1989). However, we do not
know whether such levels of resistance (3- to 10-fold) can
enable a tumour to survive the currently used chemothera-
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sies from breast cancer, myeloma and renal cell cancer have
established inverse correlations between mdrl expression and
in vitro sensitivity to MDR related drugs (Kakehi et al., 1988;
Keith et al., 1990; Salmon et al., 1989). However, for most
drugs, we do not know the in vivo concentrations to which
the tumour cells are exposed.
On the surface, there seems to be a fine correlation
between the clinical manifestation of drug resistance and
mdrl expression for a particular tumour type. Notorious
inherent drug resistant tumours such as colon and renal cell
cancers have the highest mdrl expression levels and tumours
with low or undetectable mdrl levels such as Wilms' tumours
respond much better to chemotherapy. However, this correla-
tion is misleading and does not prove a contribution of mdrl
in clinical drug resistance. Many intrinsic drug resistant
tumours with high levels of mdrl expression also do not
respond to other, MDR unrelated drugs. The MDR pheno-
type is most likely one of the many detoxification systems in
these tumour cells (Moscow & Cowan, 1990). For these
tumours, the relative contribution of MDR to clinical drug
resistance might be very small. However, recent evidence
suggests that in some specific malignancies mdrl expression
in the untreated tumour can indeed affect the outcome of
subsequent chemotherapy. For neuroblastomas (Bourhis et
al., 1989a), acute myelocytic leukaemia (AML) (Sato et al.,
1990) and soft tissue sarcomas (Chan et al., 1990), high levels
mdrl expression appeared to be associated with poor prog-
nosis.
Bourhis et al. (1989a) determined the clinical response of
primary neuroblastomas to first-line chemotherapy including
vincristine, doxorubicin and VP16. Two groups could be
distinguished. In the first, all 15 patients with undetectable or
low mdrl mRNA levels showed significant reduction in
measurable disease. In the second group of 11 patients with
high levels of mdrl expression, six showed significant reduc-
tion in measurable disease, two showed no response and in
three disease progression occurred during the course of treat-
ment. In AML, mdrl levels appeared to be most frequent in
patients with the poorest response to chemotherapy (Sato et
al., 1990). Four of five patients in whom mdrl expression was
minimal or absent showed complete remission, which lasted
for relatively long periods of time. In contrast, seven of 10
patients whose leukaemic cells contained significant mdrl
levels failed to show complete remission. In the other three
patients, a complete remission was achieved only after pro-
longed chemotherapy.
A very impressive longitudinal study was published by
Chan et al. who observed a highly significant correlation
between P-glycoprotein expression and the clinical outcome
of drug treatment in soft tissue sarcomas in childhood (Chan
et al., 1990). Chan et al. (1990) markedly improved an
immunohistochemical technique for P-glycoprotein detection
that can even be applied to formalin fixed, paraffin embedded
tissue sections. In nine of 29 soft tissue sarcomas, small
patches of P-glycoprotein positive cells were detected. These
would probably have been missed in using bulk techniques
and they appeared to be of crucial importance in the
development of drug resistance. All nine patients with P-
glycoprotein positive tumours relapsed after MDR related
chemotherapy, as compared with only one in 20 with P-
glycoprotein negative tumours. Even low levels of P-glyco-
protein expression comparable with 8-fold relative resistance
to vincristine in vitro were finally associated with clinically
significant drug resistance. As the disease progressed, the
number of P-glycoprotein positive cells and the expression
levels in individual cells increased.
Circumvention of MDR by resistance modifying agents
Tsuruo et al. made the exiting observation that noncytotoxic
doses of the calcium channel blocker verapamil could restore
the sensitivity to Vinca alkaloids in MDR cells (Tsuruo et al.,
1981). As of now, a large number of such so-called resistance
modifying agents (RMAs) has been found including: other
calcium antagonists, e.g. diltiazem, nicardipine, niludipine
(Tsuruo et al., 1985); phenothiazines (Ford et al., 1989);
indole alkaloids, e.g. reserpine (Beck et al., 1988) and reser-
pine analogs (Pearce et al., 1989) as well as other alkaloids
and amines (Zamora et al., 1988); analogs of triparanol, e.g.
tamoxifen (Ramu et al., 1984), dipyridamole (Ramu &
Ramu, 1989), and dihydropyridine (Nogae et al., 1989) and
cyclosporins (Nooter et al., 1989; Slater et al., 1986; Twenty-
man, 1988). For a number of these substances, structure/
activity relationship studies have indicated physical and
chemical features necessary to modulate MDR (Beck et al.,
1988; Ford et al., 1989; Pearce et al., 1989; Ramu & Ramu,
1989). In most cases, the reversal of resistance by RMAs is
accompanied by increased accumulation of cytotoxic agents
by the resistant cells as determined by radiolabelled drugs,
fluorescence microscopy or laser flow cytometry (Hofsli &
Nissen-Meyer, 1990; Kessel & Wilberding, 1985; Krishan et
al., 1986; Nooter et al., 1989; Tsuruo et al., 1984; Tsuruo et
al., 1982; Willingham et al., 1986; Yalowich & Ross, 1985).
The current hypothesis on the mode of action of RMAs is
that they correct the defective cytotoxic drug accumulation
by competing for outward transport directly through an
interaction, i.e., binding with P-glycoprotein (Akiyama et al.,
1988; Cornwell et al., 1987; Foxwell et al., 1989; Naito &
Tsuruo, 1989; Safa, 1988).
Clinical trials with resistance modifying agents
The finding that elevated mdrl expression can occur in
tumours and that specific agents can circumvent MDR in
model systems has stimulated the development of clinical
protocols in which RMAs are used in conjunction with
cytotoxic drugs. Pilot studies and phase I/II trials using
different RMAs and MDR related cytotoxic drugs in cancer
patients have been reported. Verapamil was used with doxo-
rubicin in ovarian cancer (Ozols et al., 1987) and with vin-
blastine and VP-16 in pediatric drug resistant tumours (Cairo
et al., 1989). Verapamil was also used in combination with
tamoxifen and doxorubicin, vincristine plus etoposide as the
initial chemotherapy in small cell lung cancer (Figueredo et
al., 1990). The combination of trifluoperazine and doxo-
rubicin was given for a variety of refractory malignancies
(Miller et al., 1988). In colon and renal cancer, cyclosporin A
was combined with epidoxorubicin and vinblastine, respec-
tively (Verweij et al., 1990). Epidoxorubicin was also given in
combination with quinidine as first line chemotherapy in
advanced breast cancer (Jones et al., 1990). These investiga-
tions, which were primarily intended as feasibility studies,
have shown that there is no dramatic increased toxicity for
normal tissues such as renal, hepatic, or intestinal epithelia
with high levels of P-glycoprotein. There was also no evi-
dence that RMAs potentiated the acute toxicities of the
cytotoxic drugs. The clinical efficacy of the experimental
protocols was assessed by the occurrence of otherwise unex-
pected tumour responses and the results overall are dis-
appointing. A shortcoming of the above mentioned studies is
a lack of data on P-glycoprotein expression in the tumours,
making an evaluation difficult. More suitable for future
studies would seem to be the haematological malignancies,
because of the possibility of repeated tumour sampling.
Promising results have been obtained in two studies, one in
multiple myeloma (Dalton et al., 1989a) and another in acute
myelocytic leukaemia (Sonneveld & Nooter, 1990). Vera-
pamil was added to the standard regimen of vincristine,
doxorubicin and dexamethasone (VAD) in patients with
refractory multiple myeloma (7) or non-Hodgkin's lymphoma
(1) (Dalton et al., 1989a). Objective clinical responses were
observed in three of eight patients who previously had been
refractory to vincristine and doxorubicin. Six of these eight
patients had evidence of P-glycoprotein expression in their
tumour cells; ofthese, two showed a partial response and one
gave a complete response for 6 months. However, three of six
P-glycoprotein positive patients did not show objective re-
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From a therapeutic point of view, important features of
MDR cells are their reduced drug accumulation and the
resulting reduced drug sensitivity, which can both be restored
by RMAs. We have shown that, in leukaemic cells expressing
mdrl, the steady-state accumulation of daunorubicin could
be significantly increased by cyclosporin A or verapamil
(Herweijer et al., 1990; Nooter et al., 1990b). Since these
RMAs inhibit the mdrl encoded drug pump, our data sug-
gest that this pump is functional in leukaemias expressing the
mdrl gene. We recently reported treatment of a refractory
AML patient with daunorubicin and cytarabine combined
with cyclosporin A (Sonneveld & Nooter, 1990). In that case,
the emergence of the MDR phenotype was monitored during
clinical progression of the disease. At relapse, a decrease in
daunorubicin accumulation by AML blasts was associated
with elevated mdrl expression and a decreased in vitro sen-
sitivity to daunorubicin. Intracellular daunorubicin accumu-
lation and in vitro sensitivity could be completely restored by
adding cyclosporin A to the cells. During progressive relapse,
the patient was treated with reinduction therapy to which
cyclosporin A was added and this resulted in elimination of
the mdrl positive AML clone. After 12 weeks, the resistant
mdrl expressing clone reappeared in the blood and bone
marrow.
In our opinion, future studies along this line in haemato-
logical malignancies should preferably include the following:
(a) RMAs are added to the cytotoxic protocols as early as
possible in the development ofclinical drug resistance; and,
(b) the efficacy of the currently used protocols, and those
to which RMAs are added, in killing mdrl expressing
tumour cells in relationship to the level of mdrl expression
are monitored by in situ methods.
Since mdrl is also frequently expressed in untreated haemato-
logical malignancies, combination therapy should also be
considered in previously untreated patients.
Another point of consideration is that the pharmacokine-
tics and, as a consequent of that the toxicity and efficacy of
cytotoxic drugs, might be influenced by the simultaneous use
of RMAs (Bright & Buss, 1990; Fedeli et al., 1989; Kerr et
al., 1986; Nooter et al., 1987). Therefore, we strongly recom-
mend animal studies in which pharmacokinetics, optimal
schedules and toxicology of combined drugs can be deter-
mined.
Supported by a grant from the Dutch Cancer Society. Dr J. Verweij
is thanked for helpful discussions and critical reading of the manu-
script.
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